問卷

TPIDB > Principal Investigator

Principal Investigator



更新時間:2026-01-01

張晃志 醫師
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

篩選

List

1Cases

2014-09-01 - 2018-11-30

Phase III

Completed
A Randomized Phase 3 Study of LY2835219 plus Best Supportive Care versus Erlotinib plus Best Supportive Care in Patients with Stage IV NSCLC with a Detectable KRAS Mutation Who Have Progressed After Platinum-Based Chemotherapy
  • Condition/Disease

    Non Small Cell Lung Cancer

  • Test Drug

    LY2835219

Participate Sites
11Sites

Terminated11Sites